Video

Associating Genes With Melanoma Risk

Author(s):

Maria T. Landi, M.D., Ph.D.
Conference|World Congress on Melanoma

Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.

Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.

The large, meta-analysis observed 27,000 patients with melanoma and 50,000 controls from the United States, Australia and Europe and discovered 19 additional genes that showed a strong correlation with melanoma risk. Included were alterations in pigmentation pathways, telomeres, immunity and signalisn and transcription pathways.

In the future, Landi and her research team will be adding about 10,000 more patients to hopefully identify more genetic associations with melanoma.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Image of bald man.
Related Content
From left: KATHLEEN COUGHLIN, M.S.N., ANP-BC, BMTCN, and ANTONIA MALONEY, B.S.N., RN, OCN
April 24th 2025

The Fearless Patient Advocate

Antonia Maloney, BSN, RN, OSN
Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.”
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation: © stock.adobe.com.
April 19th 2025

Illuminating Compassion in Cancer Care

Mike Hennessy Jr.
The journey that led to the creation of the Extraordinary Healer Award for Oncology Nursing began with a simple, yet profound, observation.
Top Cancer Headlines from 2023
January 2nd 2024

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
Image of man holding stomach.
April 6th 2025

FDA Grants HLX22 Orphan Drug Designation for Gastric Cancer

Spencer Feldman
FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.
Image of plasma cells.
April 4th 2025

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

Spencer Feldman
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.